HKMPF News and Press, Hikma Pharmaceuticals Plc From 08/07/20

Hikma Pharmaceuticals ( OTCPK:HKMPF ) : 1H Non-GAAP EPS of $0.853; GAAP EPS of $0.876. More news on: Hikma Pharmaceuticals PLC, Hikma Pharmaceuticals PLC, Earnings news and commentary, Healthcare stocks news, Read more ...

The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2020 Q2 earnings Read more ...

Here we are after a very interesting quarter. At the end of February, I was chatting with an investor friend and he mentioned the coronavirus situation in China and how it is already starting to spread in Italy. For all practical purposes, the West was treating the virus as a non-threat. "Th...

Despite the fact that I do consider as totally crazy the recent surge in major averages and that I think we have a big correction before us in the coming months, I actively search for and analyze companies to find opportunities - available now at reasonable prices or for later on, in case of a...

Irish biopharmaceutical company Amarin   (NASDAQ: AMRN) posted record revenue of $155 million in its first-quarter earnings reported April 30, marking an 112% year-over-year increase for a net loss of $20.6 million, or $0.06 per share. The company's sole product, Vascepa, is a drug derive...

Sedative for patients on ventilators currently in short supply in the US LONDON , May 12, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, announces the launch of Propofol Injectable Emulsion, USP, 20 mL, 50 mL and 100 mL Vials, in...

EATONTOWN, N.J.   , May 11, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, announces the launch of an employee matching donation campaign to support local food banks and pantries in the US communities in which Hikma operates. ...

Amarin, Corp ( AMRN ) has been an extremely turbulent and highly visible stock over the years, with investors making and losing fortunes on the volatility generated by the interim successes and failures of the company's cardiovascular therapy, Vascepa . To be sure, this drug developer has succ...

When the U.S. Food and Drug Administration approved a widened use for Amarin 's (NASDAQ: AMRN) cardiovascular drug Vascepa in December, hopes were high that it could turn into a blockbuster. However, a court ruling may have burst that bubble this week. Amarin shares sank 70% after a...

On Monday,  Amarin (NASDAQ: AMRN) investors got some horrible news. A federal judge in Nevada declared that the company's intellectual property was "obvious" and its drug patent was invalid . This was a complete shock to many investors, including yours truly. Amarin only has one drug, ...